|  | 
  
    |  | 
  
    | 
  
    |  |  |  |  
    |  | 
  
    
    | 
 The content of biopolymers in the rat prostate under combinedagonist lh-releasing hormone and androgen receptor blocker treatmentO.V. Sachinska 
V.P.Komissarenko Institute of Endocrinology andMetabolism of Academy of  Medical Sciences ofUkraine, Kiеv
 
  
 
 
Abstract
The effects of androgen receptor blocker Flutamide
(Niftolide) and/or LH-releasing hormone agonist Sur-
fagon on the nucleic acids and protein contents in the
ventral prostate of male rats were studied. It was shown
that combined drug treatment led to potentiating of
“antiprostatic” effects of  both  preparations resulted
in significant decrease of  DNA, RNA and protein
contents.
References
 
СПИСОК ЛІТЕРАТУРИ Возианов А.Ф., Резников А.Г., Клименко И.А.Эндокринная терапия рака предстательной же-лезы. - К.: Наук. думка,1999. - 280 с. Резников А.Г., Варга С.В. Антиандрогены. – М.:1988. – 208 с. Розен В.Б. Основы эндокринологии. - М.: Высш.школа, 1984. - 336 с. Шаткин А. Колориметрические методы определе-ния ДНК, РНК и белка. – В кн.: Методы виру-сологии и молекулярной биологии /Ред. К.Ха-бель, М.П.Зальцман. - М.: Мир, 1972. - С. 84-89. Braden T.D., Conn P.M. Gonadotropin-releasinghormone and its action // Can. J. Physiol. Phar-macol. -1991. - 69, N 4. - P. 445-458. Furr B.J.A., Woodburn J.R. Luteinizing hormone-releasing hormone and its analogues: a review ofbiological properties and clinical uses // J. Endo-crinol. Invest. - 1988. - 11,  N11. - P. 535-557. Labrie F., Dupont A., Cusan L. et al. Combinationtherapy with flutamide and castration (LHRHagonist or orchiectomy) in previously untreatedpatients with clinical stage D2 prostate cancer:today’s therapy of choice // J. Steroid Biochem. -1988. - 29. - P. 385-396. Sciarra F., Toscano G., Di Silverio F. Antian-drogens: clinical applications // J. Steroid Bio-chem. - 1990. - 37, N 3. - P 349-362.9. Vacher P. Gn-RH agonists in the treatment ofprostatic carcinoma// Biomedicine and Phar-macotherapy. - 1995. - 49,  N 7-8. - P. 325-331.10. Wajsman Z. Arguments for the long-term use ofcombined androgen blockade // Eur. Urol. - 1998. -34. - Suppl 3. - Р 25-28.О. В. Сачинська34 ISSN 0201-8489    Фізіол. журн., 2001, Т. 47, № 6 Waxman J.H., Sandow J., Abel P. et  al. Tow monthlydepot gonadotropin- releasing hormone agonist(buserelin) for treatment of prostatic cancer // ActaEndocrinol. - 1989. - 120, N 3. - P. 315-318. |  |  |  
    |  |  |  |  | 
  
    | © National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2025. | 
  
    |  |